Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
Schechter M, Wiviott SD, Raz I, Goodrich EL, Rozenberg A, Yanuv I, Murphy SA, Zelniker TA, Fredriksson M, Johansson PA, Leiter LA, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Cahn A, Langkilde AM, Sabatine MS, Mosenzon O. Schechter M, et al. Among authors: leiter la. Lancet Diabetes Endocrinol. 2023 Apr;11(4):233-241. doi: 10.1016/S2213-8587(23)00009-8. Epub 2023 Mar 3. Lancet Diabetes Endocrinol. 2023. PMID: 36878239 Clinical Trial.
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease.
Krishnaraj A, Bakbak E, Teoh H, Bhatt DL, Quan A, Puar P, Lambotharan B, Kirubaharan A, Firoz IN, Meglis G, Yanagawa B, Bari B, Kirubaharan R, Vijayaraghavan R, Hess DA, Demchuk AM, Mancini GBJ, Tanguay JF, Tardif JC, Voisine P, Leiter LA, Verma S. Krishnaraj A, et al. Among authors: leiter la. Med. 2023 Feb 10;4(2):130-138.e1. doi: 10.1016/j.medj.2022.12.008. Epub 2023 Jan 10. Med. 2023. PMID: 36630964 Free article.
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
Zelniker TA, Wiviott SD, Mosenzon O, Goodrich EL, Jarolim P, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Averkov O, Budaj A, Parkhomenko A, Ray KK, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Morrow DA. Zelniker TA, et al. Among authors: leiter la. JAMA Cardiol. 2023 May 1;8(5):503-509. doi: 10.1001/jamacardio.2023.0019. JAMA Cardiol. 2023. PMID: 36857035 Free PMC article. Clinical Trial.
Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.
Verma S, David JP, Leiter LA, Michelsen MM, Rasmussen S, Bhatt DL. Verma S, et al. Among authors: leiter la. Diabetes Obes Metab. 2023 Aug;25(8):2388-2392. doi: 10.1111/dom.15081. Epub 2023 May 3. Diabetes Obes Metab. 2023. PMID: 37016488 No abstract available.
Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.
Verma S, Kosmopoulos A, Bhatt DL, Fitchett D, Ofstad AP, Wanner C, Mattheus M, Zinman B, Lawler PR, Leiter LA. Verma S, et al. Among authors: leiter la. Am J Prev Cardiol. 2023 Jun 10;15:100510. doi: 10.1016/j.ajpc.2023.100510. eCollection 2023 Sep. Am J Prev Cardiol. 2023. PMID: 37384110 Free PMC article.
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.
Pitt B, Bhatt DL, Szarek M, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Ezekowitz JA, Sun F, Davies MJ, Verma S, Kosiborod MN, Steg PG; SOLOIST-WHF Investigators. Pitt B, et al. Among authors: leiter la. JACC Heart Fail. 2023 Aug;11(8 Pt 1):879-889. doi: 10.1016/j.jchf.2023.05.026. JACC Heart Fail. 2023. PMID: 37558385 Free article. Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.
Patel SM, Morrow DA, Bellavia A, Berg DD, Bhatt DL, Jarolim P, Leiter LA, McGuire DK, Raz I, Steg PG, Wilding JPH, Sabatine MS, Wiviott SD, Braunwald E, Scirica BM, Bohula EA. Patel SM, et al. Among authors: leiter la. Eur J Heart Fail. 2024 Feb;26(2):260-269. doi: 10.1002/ejhf.3118. Epub 2024 Jan 4. Eur J Heart Fail. 2024. PMID: 38131261
Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
Bohula EA, Marston NA, Ruzza A, Murphy SA, De Ferrari GM, Diaz R, Leiter LA, Elliott-Davey M, Wang H, Bhatia AK, Giugliano RP, Sabatine MS. Bohula EA, et al. Among authors: leiter la. Am Heart J. 2024 Mar;269:179-190. doi: 10.1016/j.ahj.2023.12.004. Epub 2023 Dec 29. Am Heart J. 2024. PMID: 38160917 Clinical Trial.
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.
Bakbak E, Krishnaraj A, Bhatt DL, Quan A, Park B, Bakbak AI, Bari B, Terenzi KA, Pan Y, Fry EJ, Terenzi DC, Puar P, Khan TS, Rotstein OD, Mazer CD, Leiter LA, Teoh H, Hess DA, Verma S. Bakbak E, et al. Among authors: leiter la. Med. 2024 Mar 27:S2666-6340(24)00121-1. doi: 10.1016/j.medj.2024.03.009. Online ahead of print. Med. 2024. PMID: 38552629
559 results